Allison DuRoss

I am currently in the last year of my PhD (year 5) in pharmaceutical sciences in Dr. Conroy Sun's lab. I graduated with a bachelor's degree in chemical engineering from the University of Michigan Ann Arbor in 2014. In 2015, I started in Dr. Sun's lab as a graduate student and quickly became engrossed in drug delivery research. Particularly, I became fascinated regarding the intersection between radiation therapy and nanomedicine. I believe that many advances to radiation therapy have arisen due to improvements in the physics of dose-delivery, but that the future of advancing radiation therapy will come from intelligently integrating nanomedicine into clinical radiotherapy regimens. Particularly, I think a better understanding of how radiation influences both passive and active nanoparticle accumulation is extremely important. Furthermore, I think there exist many unexplored avenues to expand the therapeutic window of radiation that involve nanomaterials.

Selected publications:

1.     DuRoss AN, Neufeld MJ, Landry MR, Rosch JG, Eaton CT, Sahay G, Thomas CR, Sun C. Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy. ACS Appl Mater Interfaces. 2019 Mar 12.

2.      DuRoss AN, Neufeld MJ, Rana S, Thomas CR Jr, Sun C. Integrating nanomedicine into clinical radiotherapy regimens. Adv Drug Deliv Rev. 2019 Jul 4.